Safety and Efficacy of Ticagrelor Monotherapy According to BMI

Obesity is growing dramatically around the world, regardless of income. For instance, 53% of US adults are obese, and 53% of people in the EU are overweight. 

¿La seguridad y eficacia de la monoterapia con Ticagrelor depende del índice de masa corporal?

The actual impact of elevated body mass index (BMI) in antiaggregation safety and efficacy, being it DAPT or SAPT, has not yet been properly looked at.  

This is a sub-analysis of the TWILIGHT (Ticagrelor with Aspirin or Alone in High-Risk Patients after Coronary Intervention), where high risk patients were randomized to 3-month DAPT followed by ticagrelor vs. ASA plus ticagrelor for 12 months. 

It included 7038 patients, 1807 presenting normal BMI (NW) (25.7%), 2927 overweight (OW) (41.6%) and 2304 obese (OB) (32.7%).

Primary end point was BARC bleeding 2-3 or 5 at 12 months.

Mean age was 64. Overweight patients tended to be younger, and more often had risk factors such as hypertension, diabetes, dyslipidemia, kidney function deterioration and prior revascularization, both PCI and CABG. 

Read also: The New Sirolimus Eluting Balloons Are Also Effective.

They more often presented acute coronary syndrome. However, OB patients presented higher rate of chronic angina. 

The transracial approach was the most often used in OB patients; they also received fewer complex PCIs. 

Primary end point resulted in favor of monotherapy vs. DAPT, regardless BMI (NW HR: 0.48 [95% CI: 0.32-0.73], OW HR: 0.57 [95% CI: 0.41-0.78] and OB HR: 0.63 [95% CI: 0.44-0.91]).

Read also: Use of OCT FFR on ACS Clinical Outcomes.

There were no differences at 12 months as regards ticagrelor monotherapy or DAPT when it came to all-cause mortality, cardiovascular mortality, MI, stroke, or definite and probable thrombosis. 

Conclusion

In high risk patients undergoing coronary PCI, both ticagrelor monotherapy and ticagrelor + aspirin  reduced bleeding events with no increase in ischemic risk across the different BMI categories. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index. 

Reference: Vijay Kunadian, et al. J Am Coll Cardiol Intv 2022;15:1948–1960.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...